Sunhawk Vision Biotech, Inc.
TTPEX:775958.80
TWD
-2.30
(-3.76%)
ISIN
TW0007759003
Return %
Stock
S&P 500
1Y
-15.52
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Su Hang Zhuo
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Kaohsiung City Taiwan
- Website
- sunhawkvision.com
- Similar Companies
- Business
- Sunhawk Vision Biotech, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, research, and development of novel nucleic acid therapeutics for the treatment of ocular surface and vision disorders. Founded in 2019 and headquartered in Taipei, Taiwan, the company utilizes proprietary microRNA (miRNA) targeting and antisense oligonucleotide (ASO) platforms to engineer topical eye drop formulations designed to address unmet medical needs in ophthalmology. The company's core product pipeline and service offerings encompass: SHJ002-MY, an anti-microRNA-328 (anti-miR-328) antisense oligonucleotide ophthalmic solution formulated as a daily topical eye drop to halt or slow axial length elongation in pediatric myopia control; SHJ002-DED, an ASO ophthalmic formulation developed to promote corneal epithelial healing, reduce ocular inflammation, and restore tear film homeostasis in patients with moderate-to-severe dry eye disease; SHJ002-RCE, an ocular regenerative formulation indicated for the treatment of recurrent corneal erosion and ocular surface damage associated with Sjögren's syndrome; and a proprietary nucleic acid drug discovery platform that provides target identification, oligonucleotide screening, and localized ocular delivery optimization for microRNA-targeted ophthalmic therapies. Sunhawk Vision Biotech operates within the biotechnology and pharmaceutical sectors, targeting healthcare providers, pediatric patients, adult ophthalmology populations, and multinational pharmaceutical partners across Taiwan, the United States, and broader international markets. The company conducts global multi-center clinical trials in compliance with international regulatory standards to advance its proprietary pipeline toward commercialization and out-licensing. In recent corporate developments, Sunhawk Vision Biotech achieved a public listing on the Taipei Exchange (TPEx) Emerging Stock Board under ticker symbol 7759 in March 2025. In January 2025, the company secured NT$243 million in private placement funding led by Qisda Corporation, with strategic participation from ophthalmic medical device manufacturer Brighten Optix and pharmaceutical distributor Norbel Baby, establishing commercial and industrial synergies across the medical sector. On the clinical front, the company successfully unblinded Phase 2 clinical data for SHJ002 in dry eye disease, demonstrating statistically significant efficacy in corneal repair, and initiated preparations for global Phase 3 pivotal trials. Additionally, the company completed subject enrollment and passed independent Data Monitoring Committee interim reviews for its multi-center Phase 2 clinical trial of SHJ002 in pediatric myopia control across clinical sites in the United States and Taiwan, while actively advancing strategic out-licensing discussions with global pharmaceutical partners.